we never talk to the ceo if i had to answer, amgen. biggest bio-tech in the world.lk about them maybe that is the reason you like them. what is the bull case on amgen >> they have done well they have a diversified portfolio. they are growing in low double digits pays a 3.5% yield. they had earnings yesterday or the day before the market was a little luke warm the if you bought on the dip, it does better the following three months we think this is a good buying opportunity for amgen. they are very shareholder oriented >> $260 median price target on the $246 stock meta, paypal, amgen. that's some drunken sailor conversation david, thank you >>> folks, i'll be off the next couple days here heading out west to colorado with this weather, how can you not? you have to get the vacation days in before the new show. that does it for us here on "worldwide exchange. nasdaq futures soaring "squawk box" is next see you next week. full prescription-strength? reduces inflammation? thank the gods. don't thank them too soon. kick pain in the aspercreme. >>> good morning the fed nudg

amgen adding 40 and united health care adding 73.orking today and what is dragging is home depot and chevron. a third of one percent lower on staples and financials are all higher and into the close you have energy, technology, materials, all of the sectors with a 1% decline. communication services also lower. but on the week as a whole, you are seeing the nasdaq out perform while the s&p 500 is down a third of 1% there is the nasdaq right now. what is helping is tesla tesla is having a rebound day. amgen is in there and t-mobile but some of the big cap tech players are under pressure today. microsoft, nvidia, apple and amazon what is also getting in the way here could be higher treasury yields, a little bit -- actually a little bit lower and higher treasury prices and a stronger dollar here this afternoon it could be weighing on the trade. wee also got some of the winners of this year a little bit under pressure. potentially taking a breather as mike santoli said. keep in mind, this is a year where we're still higher for the market

so amgen, clearly the leader in biotech t actually has been soft. i show it to you here.etty nice to place to pick it up. collegium is a smaller magnet stock. number one of all medical health care companies the way they rank up and merck, again, standard, you know, large cap, dividend payer. again amgen and merck make it also through my fact screens of the most trustworthy companies. that is why i'm sharing them with you. ashley: very good. what about in the tech sector, what do you like there? >> so if you see what i'm showing you in the tech sector, ashley, it is not what everyone else is talking about. it is not the big megacaps, which are overloaded, overowned by institutions. these three companies i'm showing you, super micro is the number one ranked of all companies in the industry again. it's a semiconductor manufacturer. you know, amot, applied, it is an amazing little company that makes molders basically going into everything, whether military, auto, semiconductors. what these all have in common is accelerating margins, accelerating revenue and a couple of them,

the top four gainers out of five are all biotech think of amgen, see jen, biogenic in gilead as well.en is raising $4 billion in debt and i saw getting more bullish in raising their target on biogen and see jen so far this week, what is biogen do they make therapies to treat alzheimer's and other cognitive disease, we know see jen does cancer therapy, i think it's a really interesting theme in a down market especially in the concerns of higher inflation and higher rates. >> they are real standouts. let's have a look at growth is it winning over value? stomach i would ask for somebody like you there is a different generational thinking. i'll tell you the younger investors will choose growth over value any day because of the long return. however, we know last year is a value play because of higher rates you have basically 400 basis points in one year in interest rates. growth this year have you looked at the speculative on profit tech names are up 100% in a.i.'s case look at the winners so far this week i told you about roku being up 70% so far this year. also draftkings you to talk to

the headliner is amgen that posted the ninth largest deal on record, selling $24 billion with an orderook of $90 billion. it was a blowout week with issuances selling more than $50 billion which was double estimates. these are the big names. it wasn't all sunshine, credit suisse had to offer investors a hefty incentive to buy its new eurobonds days after announcing a bigger than expected loss. strong data and hawkish fed speed is sending credit risk higher. this is what kathy jones at charles schwab had to say. >> we are more cautious now on credit than ever. one of the consequences of this rally has been because volatility has come down and the spreads have come down and that's giving -- getting is more cautious on credit. katie: my guests are still with us. more cautious on credit than ever is her take a what's your anxiety level when it comes to the corporate bond market? >> i just don't have anxiety about it. you rbc have to be selective and tom's comments were spot on. the bond market is offering opportunity we really haven't seen since 2007. i think there is real opportunity with

plenty of potential for payment growth and combine that with some quality measures, names that include amgenpaying 3.6% and broad, 3.2%. jack otter: there's a silver lining in higher rates which means savings accounts are raising more than they did in 15 years. carleton: ibmer when savings accounts got 5%, we are seeing it in 6-month treasuries which could be a good bet for oriented investors. one thing to keep in mind, that's more of a cash management tool that comes with investment risks. may want to look for other options for cashing in on this phenomenon. jack otter: if you think a recession is coming, you might want to 10 year bond. you've locked in higher bond. carleton: it's not just where you think the market is going but time horizon is part of the calculus, and it is very good as a cash management tool. one key, pay attention to credit quality. it can be enticing to get in on these products but they come with credit default risks. jack: you want to get an extra percentage in return for a tiny bit of risk but high-grade corporates. carleton: you want to look at the corporate bonds,

amgen is pushing the dow lower. 2020 three guidance was below expectations and it's about an acquisition of verizon therapeutics to provide the growth. the data is affecting the rest of the industry. guy: health care is where you want to hang out, the defensive area of the market. european value will be great. maybe, not so much. let's talk about the data. the inflation numbers out of the euro zone were really interesting. here's what you have to focus on. headlines coming down but core is not. does the ecb have a core strength problem? what if they need to do about that? i think the ecb is more interesting than the fed. alix: i would agree, if they're looking at 50 and 50 in march. if you have the headline number coming down in europe got luckier in terms of the weather, can christine lagarde announce of 50 point hike or does she wait and see? alix: they are further behind the fed. the fed is at the point where it is getting more nuanced and finesse the message a bit. the ecb is still in sledgehammer mode. hit this is hard to see can. we still have a core problem, an issue that we have

we have seen amgen and other biotech companies fully leaning into making bio similars, but you can thinkf as the generic version of more complicated biologic antibody type therapies. biogen has made a go of it. the challenge with bio similar is not just for biogen, but for any maker of these drugs. there's massive price erosion as more and more of them are launching. you see a decline in pricing power. so to really make this be a successful growth driver for biogen, you need to just continually launch and refresh the franchise. they sold their portion to jv. it was last year. now today we are hearing for the first time they are considering a strategic asset of that portion of their business altogether. down 10% year-over-year on the revenue basis and then a huge contributor to the top line. i think it's not an unreasonable level -- lever for them. i would argue that many that they are investigating, they will have to take advantage of it. kriti: speaking of levers, 30 seconds and on the spot, what's the bigger headwind right now? the regulatory process or potential m&a in the pipeline? m

loser like amgen, caterpillars, and unitedhealth 2% for the nasdaq, a rally for gold, a sell-off forollar. dovish reaction. that's it for me see you tomorrow, everyone now into "overtime" with scott. >> welcome to "overtime. you just heard the bells we are just getting started here what a show we have for you today. any minute meta reports its earnings that stock has rallied a lot lately we'll see if that move is justified or not, and jeffrey gunned lack joins me in just a bit. his reaction to what chair

>> amgen, biotech firm leading on arthritis and everybody's getting skinny, obesity franchise. >> health ita defense >> you like health care, though. >> we do >> thank you joey >> keyside technology. keep your eye on this company. >> "the exchange" is now >>> thank you, scott hi, everybody. i'm kelly evans. ahead this hour, is the consumer simply unnapable yesterday's cpi showed inflation is still high. retail numbers show consumer spending is still strong we'll break down the data and talk about what it means for your money >>> travel is one area that is going strong and choice hotels delivered a block buster report. we have the labor market t

microsoft, amgen and boeing the biggest drags. only cisco and home depot a higher in today's trade.or the week so far, which just shows you how strong everything has felt consumer discretionary, technology, communication services are your worst performing second source the nasdaq down the most it is breaking a three-day win streak and you have weakness in places like a microsoft, tesla on the recall, amazon, nvidia, apple. that's all weighing hard on big tech that's it for me on "closing bell." now into "overtime" with scott wapner >>> all right, sara, thank you so much. welcome to "overtime." i'm scott wapner you heard the bells. we are just getting started from post 9 at the new york stock exchange we have another big night of earnings upon us, draft kings and doordash and applied materials. we'll see the stock moves as they happen. plus, a big-time market watcher coming right here to post 9 to argue why an even bigger pullback than what we saw today might be coming. we'll debate that call, what it might mean for your money moving forward. we do begin, though, with our "talk of th

there's a couple of win winners, amgen and coca-cola, the rest are on the downside.cially. as for the s&p 500, also lore to the sign of -- to the tune of close to 1%, and 1.25% down on the nasdaq. let's have a look at big tech. any winners there at all? yes. meta platforms is up just a fraction, apple's down, microsoft is down 1.5%. alphabet's down and amazon dropping 2% to $95. a couple of big retailers reported before the bell this morning. susan's with us. start with walmart, please. susan: the second year in a row that america's biggest retailer is forecasting profit to the fall. isn't that surprising? second year in a row. now, last year they had inventory issues, this year they're trying to slowly kill the out of that, so they're forecasting a 6% plus drop in this year's earnings. also you saw that same-store sales were also a bit light of wall street estimates. demand waned for apparel and home goods, and they're going to groceries. grocery sales are booming because wealthier clients are coming down because of high inflation to buy at cheaper places with 40-ye

gains in amgen, unitedhealth, merck helping to propel the dow into positive territory today. still for the week, here we go, the dow and the s&p 500 have given back their gains from earlier this week, and stocks remain under pressure from hotter than expected inflation data this week and some very hawkish fed talk. we're going to get into that in just a few moments. in fact, just yesterday st. louis fed president james bullard sent is markets into a tailspin chen he said he would not -- when he said he would not rule out a 50 basis point hike, thenned today tom barkin said he supports a 25 basis point hike. either way, the fed is still believing it's got some work to do ahead. bar kin also said that the labor market is still quite hot and9 that the u.s. is making slow progress on inflation. now as the 2-year treasury climbs to its highest level in 3 month, many investors are ducking into bonds. they're looking for a safe haven. but could plaguing it safe have some -- playing it safe have some hidden dangers? let's get right to the floor show to find out where investors should

i amgen fer casarian and i work here at san francisco international airport. the idea for therapy dogs got started the day after 9/11. an employee brought his therapy dog to work after 9/11 and he was able to see how his dog was able to relieve passenger's jitter. when we first launched the program back in 2013, our main goal was to destress our passengers however what we quickly found is that our animals were helping us find a way to connect with our pang. passengers. we find there are a lot of people traveling through the airport who are missing their pets and who are on their road a lot and can't have pets and we have come in contact with a lot of people recently who have lost pet. >> i love the wag brigade. >> one of my favorite parts is walking into the terminals and seeing everybody look up from their device, today everybody is interacting on their cell phone or laptop and we can walk into the terminal with a dog or a pig and people start to interact with each other again and it's on a different level. more of an emotional level. >> i just got off an 11.